Q: Who should receive the shingles vaccine?

Cleveland Clinic Journal of Medicine

Volumn 76, Issue 1, 2009, Pages 45-48

  Singh, Aparajita ^a   Englund, Kristin ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VARICELLA ZOSTER VACCINE;

AGED; ARTICLE; COST BENEFIT ANALYSIS; ECONOMICS; HERPES ZOSTER; HUMAN; IMMUNOLOGY; UNITED STATES; VACCINATION; VARICELLA ZOSTER VIRUS;

AGED; COST-BENEFIT ANALYSIS; HERPES ZOSTER; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; UNITED STATES; VACCINATION;

EID: 60849096118     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.75a.08046     Document Type: Article

References (20)

1. Nagel MA, Gilden DH. The protean neurologic manifestations of varicella-zoster virus infection. Cleve Clin J Med 2007; 74:489-504.
2. Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002; 347:340-346.
3. Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis 2004; 39:342-348.
4. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965; 58:9-20.
5. Lydick E, Epstein RS, Himmelberger D, White CJ. Herpes zoster and quality of life: a self-limited disease with severe impact. Neurology 1995; 45:S52-S53.
6. Kost RG, Straus SE. Postherpetic neuralgia - pathogenesis, treatment, and prevention. N Engl J Med 1996; 335:32-42.
7. Johnson R, McElhaney J, Pedalino B, Levin M. Prevention of herpes zoster and its painful and debilitating complications. Int J Infect Dis 2007; 11(suppl 2):S43-S48.
8. Oxman MN, Levin M J, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-2284.
9. Burke MS. Herpes zoster vaccine: clinical trial evidence and implications for medical practice. J Am Osteopath Assoc 2007; 107(suppl 1):S14-S18.
10. Betts RF. Vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia. J Am Acad Dermatol 2007; 57(suppl):S143-S147.
11. Kroger AT, Atkinson WL, Marcuse EK, Pickering LK. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1-48.
12. Merck. Zostavax zoster vaccine live suspension for subcutaneous injection. www.merck.com/product/usa/pi_circulars/z/zostavax_pi.pdf. Accessed 11/17/2008.
13. Holodniy M. Prevention of shingles by varicella zoster virus vaccination. Expert Rev Vaccines 2006; 5:431-443.
14. Herpes zoster vaccine (Zostavax). Med Lett Drugs Ther 2006; 48:73-74.
15. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995; 155:1605-1609.
16. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1-30.
17. Bader MS. Immuunization for the elderly. Am J Med Sci 2007; 334:481-486.
18. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol 2003; 70(suppl 1):5111-S118.
19. Dworkin RH, White R, O'Connor AB, Baser O, Hawkins K. Healthcare costs of acute and chronic pain associated with a diagnosis of herpes zoster. J Am Geriatr Soc 2007; 55:1168-1175.
20. Dworkin RH, White R, O'Connor AB, Hawkins K. Health care expenditure burden of persisting herpes zoster pain. Pain Med 2008; 9:348-353.